These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10718620)

  • 1. Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.
    Chakraborty D; Bhattacharyya M
    Mol Cell Biochem; 2000 Jan; 204(1-2):17-20. PubMed ID: 10718620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
    Moosavi-Movahedi AA; Mousavy SJ; Divsalar A; Babaahmadi A; Karimian K; Shafiee A; Kamarie M; Poursasan N; Farzami B; Riazi GH; Hakimelahi GH; Tsai FY; Ahmad F; Amani M; Saboury AA
    J Biomol Struct Dyn; 2009 Dec; 27(3):319-39. PubMed ID: 19795915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients.
    Korkina L; De Luca C; Deeva I; Perrotta S; Nobili B; Passi S; Puddu P
    Transfus Sci; 2000 Dec; 23(3):253-4. PubMed ID: 11099907
    [No Abstract]   [Full Text] [Related]  

  • 5. Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1.
    Afanas'ev IB; Afanas'ev II; Deeva IB; Korkina LG
    Transfus Sci; 2000 Dec; 23(3):237-8. PubMed ID: 11099899
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
    Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ
    Free Radic Biol Med; 2015 Jan; 78():118-22. PubMed ID: 25451643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral iron chelator L1 on iron absorption in man.
    Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
    Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
    Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation in chemotherapy.
    Weinberg ED
    Adv Appl Microbiol; 2003; 52():187-208. PubMed ID: 12964245
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.
    Xie YY; Lu Z; Kong XL; Zhou T; Bansal S; Hider R
    Eur J Med Chem; 2016 Jun; 115():132-40. PubMed ID: 27014847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the interaction between DNP and DIDS with human hemoglobin as binary and ternary systems: spectroscopic and molecular modeling investigation.
    Rashidipour S; Naeeminejad S; Chamani J
    J Biomol Struct Dyn; 2016; 34(1):57-77. PubMed ID: 25692655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone: structural and functional modulating agent of hemoglobin fructation.
    Sattarahmady N; Heli H; Moosavi-Movahedi AA; Karimian K
    Mol Biol Rep; 2014 Mar; 41(3):1723-9. PubMed ID: 24415298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
    Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison and investigation of bovine hemoglobin binding to dihydroartemisinin and 9-hydroxy-dihydroartemisinin: spectroscopic characterization.
    Xiao M; Han L; Zhou L; Zhou Y; Huang X; Ge X; Wei S; Zhou J; Wu H; Shen J
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 May; 125():120-5. PubMed ID: 24531541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
    Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP
    Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN; Kontoghiorghes GJ
    Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oral 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in different ferrokinetic models in animals and humans.
    Kontoghiorghes GJ
    Br J Haematol; 1991 Mar; 77(3):440-2. PubMed ID: 2064649
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron mobilisation from transferrin by deferiprone (L1).
    Kontoghiorghes GJ; Kolnagou A; Eracleous E; Evans RW
    Br J Haematol; 2005 Apr; 129(1):157. PubMed ID: 15801969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.